Article
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.
Antimicrobial agents and chemotherapy - 1 Jun 2002
Wei Xiping, Decker Julie M, Liu Hongmei, Zhang Zee, Arani Ramin B, Kilby J Michael, Saag Michael S, Wu Xiaoyun, Shaw George M, Kappes John C
Abstract excerpt
The synthetic peptide T-20 (enfuvirtide) represents the first of a new class of antiretroviral compounds to demonstrate in vivo potency by targeting a step in viral entry. T-20 inhibits a conformational change in the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein (gp41) that is required for fusion between HIV-1 and target cell membranes. The initial phase I clinical trial of T-20 treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.